RETRACTED ARTICLE: A comparison of risk factors for age-related macular degeneration and polypoidal choroidal vasculopathy in Chinese patients

Chen, Xiaoli; Hu, Qingping; Bai, Yujing; Deng, Yu; Wang, Hai-Wei; Liu, Shan; Wang, Yin‐Lin; Yue, Yankun

doi:10.1007/s00417-018-4020-y

Cited by 7 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCV and CNV are two subtypes of wAMD. They have many common clinical characteristics and risk factors, but there are also many different epidemiological characteristics, indicating that they have different pathophysiological processes (48)(49)(50). These differences have led to a certain difference in the therapeutic effect between intravitreal injection of anti-VEGF drugs on PCV and CNV (51,52).…”

Section: Discussionmentioning

confidence: 99%

Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up

Huang

Zhang

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Purpose: To evaluate the treatment solutions and effectiveness of intravitreal ranibizumab (RBZ) or conbercept in patients with wet age-related macular degeneration (wAMD) in a real-life setting in China.Methods: The medical records of 368 patients with wAMD who started RBZ or conbercept treatment between 1 May 2014 and 30 April 2018 were evaluated. All patients were defined on fundus angiography at baseline to determine the subtype of AMD (PCV or CNV). We report visual acuity (VA) and central retinal thickness (CRT) measurements at baseline and 12 months.Results: The average number of anti-VEGF injections was 2.1 ± 1.2. The BCVA improvement of these two groups was similar with a difference of 1.00 letter (95% CI: −1.4~3.4, p = 0.8505). At the end of the study, a BCVA increase of at least 5 letters was determined to be a satisfactory efficacy endpoint. Several factors were related to the possible improvement in the satisfactory efficacy endpoint, including female sex (OR 2.07, 95% CI 1.22~3.51), number of injections (OR 1.40, 95% CI 1.12~1.75) and VA change at the first month (OR 13.75, 95% CI 7.41~25.51). Additionally, some factors were related to the possible reduction in the satisfactory efficacy endpoint, including diabetes (OR 0.27, 95% CI 0.10~0.73) and disease history (OR 0.75, 95% CI 0.57~0.98).Conclusion: Our study demonstrates that anti-VEGF drugs can effectively improve BCVA and reduce CRT in AMD patients. Sex, number of injections, VA change at the first month, diabetes and disease history are the most important factors affecting visual acuity.

show abstract

Section: Discussionmentioning

confidence: 99%

Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up

Huang

Zhang

et al. 2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“…A variety of factors lead to the development of nAMD, which is mainly characterized as the formation of CNV via the action of multiple cytokines (such as VEGF, angiopoietin, inflammatory factors, insulin-like growth factor1, cyclooxygenase-2, chemokine receptor-3, and primary fibroblast growth factor). Any of these cytokines causes damage to Bruch’s membrane, which in turn is accompanied by a relative or absolute increase in VEGF and aggregation of inflammatory factors, leading to the occurrence of CNV ( Cheung et al, 2017 ; Chen et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

Spectral-domain optical coherence tomography combined with electroretinography in the assessment of conbercept for neovascular age-related macular degeneration: a preliminary study

Wang

2023

Front. Neurosci.

View full text Add to dashboard Cite

ObjectiveTo observe the effect of three consecutive intravitreal injections of conbercept in the treatment of neovascular age-related macular degeneration (nAMD), to investigate the correlation between retinal anatomy and retinal function by spectral-domain optical coherence tomography (SD-OCT) and electroretinography (ERG), to evaluate the short-term clinical efficacy of conbercept in the treatment of nAMD, and to explore the value of ERG as a predictor of treatment efficacy.MethodA retrospective investigation was conducted on 36 patients (36 eyes) treated with intravitreal injections of conbercept at 0.5 mg a month for three consecutive courses. Data collected included the best corrected visual acuity (BCVA), central retinal thickness (CRT), retinal pigment epithelium (RPE) elevation volume in 1 mm-diameter (1RV), 3 mm-diameter (3RV), and 6 mm-diameter circles around the fovea (6RV), amplitude density and latency of the P1 wave in the multifocal electroretinography (mf-ERG) R1 ring and amplitude and latency in full-field electroretinography (ff-ERG) at baseline and monthly. The paired t test was used to compare the difference between pre- and posttreatment. Pearson correlation analysis was used to analyze the correlation between macular retinal structure and function. The difference was significant when p < 0.05.ResultsAt 12 weeks, the BCVA, CRT, 1RV, 3RV, 6RV, the P1 wave amplitude density of the mf-ERG R1 ring and the ff-ERG amplitude parameters were all significantly improved (p < 0.001). The BCVA in logMAR was positively correlated with CRT; 1RV, 3RV, and 6RV were negatively correlated with the amplitude density and latency of the mf-ERG R1 ring P1 wave. There were no severe ocular or systemic complications during the follow-up period.ConclusionConbercept is useful for the short-term treatment of nAMD. It can safely improve the visual acuity of affected eyes and restore the structure and function of the retina. ERG could serve as an objective indicator of function for evaluating the efficacy of and determining the need for retreatment during nAMD treatment.

show abstract

“…O fator de risco positivo com maior significância estatística nesta pesquisa foi o tabagismo (p=0,03), o que é comprovado na literatura como relevante no desenvolvimento da DMRI. (20)(21)(22) Podem ser consideradas como limitações deste estudo a pequena amostragem e o fato de ter sido realizado num hospital universitário, de encaminhamento de referência terceirizada no tratamento dos casos avançados de DMRI. Esse fato pode até ter sobressaído indiretamente nesta amostragem referente ao tabagismo.…”

Section: Discussionunclassified

Perfil epidemiológico de pacientes com degeneração macular relacionada à idade

Carvalho,

Rodrigues,

Oda

et al. 2023

Revista Brasileira De Oftalmologia

View full text Add to dashboard Cite

show abstract

RETRACTED ARTICLE: A comparison of risk factors for age-related macular degeneration and polypoidal choroidal vasculopathy in Chinese patients

Abstract: The risk factors for nAMD and PCV is varying with the exception of smoking. Our findings suggest that different strategies might be applied in the clinical management and scientific research on nAMD and PCV.

Cited by 7 publications

References 44 publications

Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up

Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up

Spectral-domain optical coherence tomography combined with electroretinography in the assessment of conbercept for neovascular age-related macular degeneration: a preliminary study

Perfil epidemiológico de pacientes com degeneração macular relacionada à idade

Contact Info

Product

Resources

About